Evidence map›Paper›PMID 39207868›Full record

ArticleBlood advances2024

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

Florence Rabian, David Beauvais, Tony Marchand, Sabine Fürst, Anne Huynh, Eolia Brissot, Sébastien Maury, Ludovic Gabellier, Patrice Chevallier, Michael Loschi and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. [CAR T cell therapy in acute lymphoblastic leukemia].Innere Medizin (Heidelberg, Germany) · 2025
    Review
  6. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Florence RabianHematology Adolescents and Young Adult Division, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.ORCID 0000-0002-9695-193X
David BeauvaisHematology Department, Centre Hosiptalo-Universitaire (CHU) Lille, Université Lille, Institut National de la Santé et de la Recherche Médicale (INSERM) U-1192 PRISM, Lille, France.ORCID 0000-0003-1866-828X
Tony MarchandHematology Department, CHU Rennes, Rennes, France.
Sabine FürstHematology Department, Institut Paoli-Calmettes, Marseille, France.
Anne HuynhHematology Department, CHU Toulouse/Institut universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France.ORCID 0000-0001-8462-6198
Eolia BrissotDepartment of Haematology, Sorbonne University, Saint Antoine Hospital, INSERM UMR 938, Paris, France.
Sébastien MauryHematology Department, Hôpitaux universitaires Henri Mondor AP-HP and Université Paris Est Créteil, Créteil, France.ORCID 0000-0002-1170-8683
Ludovic GabellierDepartment of Clinical Hematology, University Hospital of Montpellier, Montpellier, France.
Patrice ChevallierHematologie Department, CHU de Nantes, Nantes, France.
Michael LoschiHematology Department, Nice University Hospital, Cote d'Azur University, Nice, France.ORCID 0000-0002-4460-5939
Stéphanie NguyenHematology Department, Sorbonne Université, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
Marie BalsatHématology Department, Hospices Civils de Lyon (HCL), Hôpital Lyon Sud, Pierre-Bénite, France.
Ingrid LafonHematology Department, Institut de Cancérologie de Bourgogne, Polyclinique du Parc Drevon, Dijon, France.
Amandine FayardDepartment of Clinical Hematology and Cell Therapy, CHU Estaing, Clermont-Ferrand, France.
Vincent CamusDepartment of Hematology, Centre Henri Becquerel, Rouen, France.ORCID 0000-0002-1559-007X
Célestine SimandDepartment of Hematology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Niels MoyaHematology Department, CHU Poitiers, Poitiers, France.
Cristina Castilla-LlorenteDepartment of Hematology, Gustave Roussy Cancer Campus, Villejuif, France.
Magalie JorisDepartment of Clinical Hematology and Cell Therapy, CHU Amiens, Amiens, France.
Ana BerceanuDepartment of Clinical Hematology, CHU de Besançon, Besançon, France.
Anne Thiebaut-BertrandDepartment of Clinical Hematology, CHU Grenoble Aples, Grenoble, France.
Véronique LhéritierHematology Department, Coordination Group for research on Adult Acute Lymphoblastic Leukemia (GRAALL), HCL, Hôpital Lyon Sud, Pierre-Bénite, France.
Eve GehlkopfMedical and Scientic Department, The Lymphoma Academic Research Organisation (LYSARC), Hôpital Lyon Sud, Pierre-Bénite, France.
Gabrielle Roth-GuépinDepartment of Clinical Hematology, CHU NANCY, Vandoeuvre Les Nancy, France.
Thibaut LeguayHematology Department, CHU Bordeaux, Hôpital du Haut-Lévêque, Pessac, France.ORCID 0000-0002-3123-4948
Nicolas BoisselHematology Adolescents and Young Adult Division, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.ORCID 0000-0003-2091-7927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39207868
PMCPMC11532742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.